Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by absolute change from baseline at week 52, compared to placebo. 1,2 Nerandomilast's safety and tolerability profile was consistent across both trials, with similar rates of permanent treatment discontinuation to placebo. 1,2 In both trials the composite key secondary endpoint (time to...

Ingelheim am Rhein, 19/05/2025 (informazione.news - comunicati stampa - salute e benessere)